Strata Skin Sciences, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
STRATA Skin Sciences reported a net loss of $1.6 million in Q3 2025 on reduced revenues, but secured its liquidity for the next 12 months by pausing debt covenants and raising capital.
OTC.Pink
STRATA Skin Sciences reported a significant increase in net losses and a shift to negative working capital for the quarter ended June 30, 2025, alongside declining revenues and an un-remediated material weakness in internal controls.
OTC.Pink
Strata Skin Sciences' Q1 2025 results show stable revenue with a reduced net loss compared to the same period last year.
OTC.Pink
Strata Skin Sciences reports a slight decrease in revenue for the third quarter of 2024 compared to the same period last year, alongside a net loss, but shows improved gross profit margins.
OTC.Pink
Strata Skin Sciences experienced a slight revenue increase in Q2 2024, but faced challenges with profitability and a decrease in XTRAC system placements.
OTC.Pink
Strata Skin Sciences reported a net loss of $3.368 million for the first quarter of 2024, impacted by lower revenues and increased costs.